89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatmentOosting, S. F., Brouwers, A. H., van Es, S. C., Nagengast, W. B., Oude Munnink, T. H., Lub-de Hooge, M. N., Hollema, H., de Jong, J. R., de Jong, I. J., de Haas, S., Scherer, S. J., Sluiter, W. J., Dierckx, R. A., Bongaerts, A. H. H., Gietema, J. A. & de Vries, E. G. E., Jan-2015, In : Journal of Nuclear Medicine. 56, 1, p. 63-69 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Targeted Gynaecologic Oncology (TARGON)
- Polymer Mixtures and Computer Simulations
- Molecular Neuroscience and Ageing Research (MOLAR)
- Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
UNLABELLED: No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be useful. We determined tumor uptake of (89)Zr-bevacizumab, a VEGF-A-binding PET tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study.
METHODS: Patients underwent (89)Zr-bevacizumab PET scans at baseline and 2 and 6 wk after initiating either bevacizumab (10 mg/kg every 2 wk) with interferon-α (3-9 million IU 3 times/wk) (n = 11) or sunitinib (50 mg daily, 4 of every 6 wk) (n = 11). Standardized uptake values were compared with plasma VEGF-A and time to disease progression.
RESULTS: (89)Zr-bevacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV(max) (maximum standardized uptake value) of 6.9 (range, 2.3-46.9). Bevacizumab/interferon-α induced a mean change in tumor SUV(max) of -47.0% (range, -84.7 to +20.0%; P < 0.0001) at 2 wk and an additional -9.7% (range, -44.8 to +38.9%; P = 0.015) at 6 wk. In the sunitinib group, the mean change in tumor SUV(max) was -14.3% at 2 wk (range, -80.4 to +269.9; P = 0.006), but at 6 wk the mean change in tumor SUV(max) was +72.6% (range, -46.4 to +236%; P < 0.0001) above baseline. SUV(max) was not related to plasma VEGF-A at all scan moments. A baseline mean tumor SUV(max) greater than 10.0 in the 3 most intense lesions corresponded with longer time to disease progression (89.7 vs. 23.0 wk; hazard ratio, 0.22; 95% confidence interval, 0.05-1.00).
CONCLUSION: Tumor uptake of (89)Zr-bevacizumab is high in mRCC, with remarkable interpatient and intrapatient heterogeneity. Bevacizumab/interferon-α strongly decreases tumor uptake whereas sunitinib results in a modest reduction with an overshoot after 2 drug-free weeks. High baseline tumor SUV(max) was associated with longer time to progression.
|Number of pages||7|
|Journal||Journal of Nuclear Medicine|
|Publication status||Published - Jan-2015|
- renal cell carcinoma, molecular imaging, positron emission tomography, bevacizumab, sunitinib, ENDOTHELIAL GROWTH-FACTOR, METASTATIC BREAST-CANCER, PHASE-III TRIAL, INTERFERON-ALPHA, ANTI-VEGF, BEVACIZUMAB, SUNITINIB, EFFICACY, IN-111-BEVACIZUMAB, BIODISTRIBUTION